Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 12/20 | 0.55 |
| ▸ | KDR | P35968 | 15/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.48 |
| ▸ | KIT | P10721 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | FLT4 | P35916 | 2/20 | 0.43 |
| ▸ | CIT | O14578 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | HLA-A | P04439 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | FRK | P42685 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | STK3 | Q13188 | 1/20 | 0.43 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1652660 | 0.83 | KDR (0.69) | FLT1KDRPDGFRBKITMEN1 | |
| SCHEMBL1651296 | 0.82 | FLT1 (0.79) | FLT1KDRPDGFRBKITMEN1 | |
| SCHEMBL1385235 | 0.82 | NAMPT (0.46) | FLT1KDRPDGFRBKITMEN1 | |
| SCHEMBL4818044 | 0.81 | KDR (0.79) | FLT1KDRPDGFRBKITCSF1R | |
| SCHEMBL14267795 | 0.80 | FLT1 (0.63) | FLT1KDRPDGFRBKITMEN1 | |
| SCHEMBL5753928 | 0.78 | KDR (0.70) | FLT1KDRPDGFRBKITMEN1 | |
| SCHEMBL1651994 | 0.78 | KDR (0.64) | FLT1KDRPDGFRBKITMEN1 | |
| SCHEMBL5753555 | 0.77 | FLT1 (0.80) | FLT1KDRPDGFRBKITMEN1 | |
| SCHEMBL14267794 | 0.74 | FLT1 (0.65) | FLT1KDRPDGFRBKITMEN1 | |
| SCHEMBL1386811 | 0.74 | KDR (0.44) | FLT1KDRMEN1KMT2ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4673977-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| EP-1165085-B1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2006-06-14 | — | — | EP | claimed |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2005-08-11 | — | — | US | claimed |
| US-6911440-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2005-06-28 | — | — | US | claimed |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2004-07-22 | — | — | US | claimed |
| US-6686347-B2 | RHEUMATIC DISEASES; ANALGESICS; ENZYME INHIBITORS | NOVARTIS AG (CH) | 2004-02-03 | — | — | US | claimed |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2003-01-16 | — | — | US | claimed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| WO-2014194312-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRIAN TUMOR | DEL MAR PHARMACEUTICALS (CA) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014168986-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2014-10-16 | — | — | WO | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| WO-2013169600-A1 | VETERINARY USE OF DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, AND DIBROMODULCITOL TO TREAT MALIGNANCIES | DELMAR PHARMACEUTICALS (CA) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013142817-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2013-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | FLT1 3556/4885KDR 3803/4885PDGFRB 4079/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | FLT1 3556/4885KDR 3803/4885PDGFRB 4079/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | FLT1 3556/4885KDR 3803/4885PDGFRB 4079/4885 |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, KDR, FFAR2 | FLT1 1/4885KDR 2/4885PDGFRB 65/4885 |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, FLT1, TIE1 | FLT1 2/4885KDR 1/4885PDGFRB 41/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | FLT1 3556/4885KDR 3803/4885PDGFRB 4079/4885 |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, FLT4, KDR | FLT1 1/4885KDR 3/4885PDGFRB 77/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | FLT1 1351/4885KDR 1640/4885PDGFRB 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.